Senior Principal Investigator: Xavier Santamaria

The endometrium has a high regenerative capacity, mainly controlled by stem cells. Endometrial stem cells reside in the basalis of the endometrium; however, other sources of stem cells, such as the bone marrow, also contribute to endometrial tissue homeostasis. Damage to the stem cell niche results in the replacement of bona fide endometrium with fibrotic endometrium, which leads to endometrial atrophy or Asherman’s Syndrome.

Our group demonstrated the therapeutic potential of autologous bone marrow CD133+ stem cells in treating endometrial pathologies such as Asherman’s syndrome or endometrial atrophy.

We are currently conducting a Phase II clinical trial that aims to confirm the safety of this therapy and obtain a deeper understanding of the effects and mechanisms of action of CD133+ bone marrow stem cell therapy. This knowledge will help us design specific, targeted therapies to effectively treat this incurable condition.

To learn more about what we do and access our main publications, visit